← Back to Screener
Ascentage Pharma Group International American Depository Shares (AAPG)
Price$26.36
Favorite Metrics
Price vs S&P 500 (26W)-42.38%
Price vs S&P 500 (4W)7.13%
Market Capitalization$2.86B
All Metrics
Book Value / Share (Quarterly)$0.52
P/TBV (Annual)13.21x
Revenue Growth (3Y)39.89%
Cash Flow / Share (Quarterly)$-0.09
Price vs S&P 500 (YTD)-4.70%
Gross Margin (TTM)91.48%
Net Profit Margin (TTM)-216.47%
EPS (TTM)$-0.51
10-Day Avg Trading Volume2.61M
EPS Excl Extra (TTM)$-0.51
Revenue Growth (5Y)115.16%
EPS (Annual)$-0.51
ROI (Annual)-37.61%
Gross Margin (Annual)91.48%
Net Profit Margin (5Y Avg)-779.84%
Cash / Share (Quarterly)$0.97
Revenue Growth QoQ (YoY)116.96%
ROA (Last FY)-31.35%
Revenue Growth TTM (YoY)-41.46%
EBITD / Share (TTM)$-0.47
ROE (5Y Avg)-411.76%
Operating Margin (TTM)-205.93%
Cash Flow / Share (Annual)$-0.06
P/B Ratio12.84x
P/B Ratio (Quarterly)12.55x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)28.78x
Net Interest Coverage (TTM)-21.99x
ROA (TTM)-35.46%
EPS Incl Extra (Annual)$-0.51
Current Ratio (Annual)1.79x
Quick Ratio (Quarterly)1.66x
3-Month Avg Trading Volume2.14M
52-Week Price Return46.39%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.49
P/S Ratio (Annual)29.63x
Asset Turnover (Annual)0.14x
52-Week High$95.35
Operating Margin (5Y Avg)-787.36%
EPS Excl Extra (Annual)$-0.51
CapEx CAGR (5Y)-21.49%
Tangible BV CAGR (5Y)8.99%
26-Week Price Return-33.63%
Quick Ratio (Annual)1.66x
13-Week Price Return-5.76%
Total Debt / Equity (Annual)1.49x
Current Ratio (Quarterly)1.79x
Enterprise Value$2,418.488
Revenue / Share Growth (5Y)94.64%
Asset Turnover (TTM)0.16x
Book Value / Share Growth (5Y)-1.08%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.78x
Pretax Margin (Annual)-215.29%
Cash / Share (Annual)$0.97
3-Month Return Std Dev53.77%
Gross Margin (5Y Avg)90.47%
Net Income / Employee (TTM)$-0
ROE (Last FY)-93.83%
Net Interest Coverage (Annual)-24.07x
EPS Basic Excl Extra (Annual)$-0.51
Receivables Turnover (TTM)3.42x
Total Debt / Equity (Quarterly)1.49x
EPS Incl Extra (TTM)$-0.51
Receivables Turnover (Annual)3.42x
ROI (TTM)-43.71%
P/S Ratio (TTM)29.63x
Pretax Margin (5Y Avg)-816.16%
Revenue / Share (Annual)$0.24
Tangible BV / Share (Annual)$0.49
Price vs S&P 500 (52W)45.75%
Year-to-Date Return-1.44%
5-Day Price Return3.79%
EPS Normalized (Annual)$-0.51
ROA (5Y Avg)-28.33%
Net Profit Margin (Annual)-216.47%
Month-to-Date Return11.96%
Cash Flow / Share (TTM)$-0.48
EBITD / Share (Annual)$-0.46
Operating Margin (Annual)-205.93%
LT Debt / Equity (Annual)0.56x
ROI (5Y Avg)-36.46%
LT Debt / Equity (Quarterly)0.56x
EPS Basic Excl Extra (TTM)$-0.51
P/TBV (Quarterly)13.21x
P/B Ratio (Annual)12.55x
Inventory Turnover (TTM)2.78x
Pretax Margin (TTM)-215.29%
Book Value / Share (Annual)$0.52
Price vs S&P 500 (13W)-8.63%
Beta1.27x
Revenue / Share (TTM)$0.23
ROE (TTM)-124.87%
52-Week Low$36.50
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International American Depository Shares | 29.63x | -41.46% | 91.48% | — | $26.36 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Ascentage Pharma is a clinical-stage biotechnology company developing novel small-molecule therapies for cancers, hepatitis B, and age-related diseases. The company's platform uses protein-protein interaction inhibitors to restore cancer cell apoptosis, with primary focus on hematological malignancies. Operations span the United States and China.